The GPR171 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population with disrupted GPR171 in the A2780 human ovarian cancer cell line. This polyclonal product, derived from a non-clonal pool of edited cells, provides a heterogeneous knockout model reflecting varied editing outcomes. The CRISPR/Cas9-mediated gene disruption establishes a loss-of-function system suitable for studying GPR171 biology without clonal isolation. As a polyclonal population, it offers a robust tool for high-throughput applications and pathway analyses where clonal uniformity is not required.
The A2780 cell line is an established model of human ovarian endometrioid adenocarcinoma, originally from an untreated patient. These epithelial cells are widely used in ovarian cancer research, especially for drug sensitivity and resistance studies. A2780 cells show reproducible growth and molecular features ideal for gene editing. Their use in this knockout model enables direct assessment of GPR171 function in an ovarian adenocarcinoma context, aiding translation to clinical scenarios.
GPR171 is a G protein?Ccoupled receptor that binds the BigLEN neuropeptide, processed from proSAAS. Upon ligand binding, GPR171 couples to G??i/o proteins, inhibiting adenylate cyclase to reduce intracellular cAMP. This decrease attenuates PKA and modulates MAPK/ERK and PI3K/AKT signaling. Downstream effectors include ERK1/2, AKT, CREB, and cell cycle/apoptosis regulators like cyclin D1 and BCL2 members. GPR171 signaling is regulated by ??-arrestins, GPCR kinases, and potentially RAMPs.
In A2780 ovarian cancer cells, GPR171-mediated signaling influences proliferation, survival, and migration. Coupling to G??i/o activates MAPK/ERK and PI3K/AKT pathways, promoting oncogenic phenotypes. Disruption of GPR171 is expected to impair these tumorigenic properties, providing a model to dissect neuropeptide?CGPCR axes in ovarian cancer progression. This system allows direct evaluation of A2780 cell dependency on GPR171 for growth and metastasis.
The knockout product supports diverse applications: functional characterization of GPR171 in ovarian cancer, high-throughput antagonist screening, and neuropeptide?CGPCR signaling studies. Compatible assays include MTS/MTT proliferation, Transwell migration/invasion, Annexin V apoptosis, western blotting for ERK/AKT, cAMP ELISA, RT-qPCR, and flow cytometry. The polyclonal nature suits pooled screening and validation. For further details or custom applications, contact Ascent Research.
